Research Analysts Issue Forecasts for MLTX FY2026 Earnings

Key Points

• HC Wainwright cut its FY2026 earnings forecast for MoonLake Immunotherapeutics to a loss of $3.58 per share from $3.17, while maintaining a Buy rating and a $50 price target. The consensus FY2026 estimate is a loss of $3.45 per share.
• Analyst views are mixed but lean positive: MarketBeat reports a Moderate Buy consensus rating and an average price target of $31.09, with 10 Buy, two Hold, and two Sell ratings.
• MoonLake reported a quarterly loss of $0.93 per share, missing the $0.83-per-share consensus estimate; its stock opened at $12.56 on Wednesday.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Analysts at HC Wainwright lowered their FY2026 EPS estimates for shares of MoonLake Immunotherapeutics in a research report issued to clients and investors on Monday, November 9th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($3.58) per share for the year, down from their prior estimate of ($3.17). HC Wainwright currently has a "Buy" rating and a $50.00 price target on the stock. The consensus estimate for MoonLake Immunotherapeutics' current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics' Q4 2026 earnings at ($0.84) EPS, Q1 2027 earnings at ($0.79) EPS, Q2 2027 earnings at ($0.77) EPS, Q3 2027 earnings at ($0.82) EPS, Q4 2027 earnings at ($0.63) EPS and FY2027 earnings at ($3.01) EPS.

Other equities research analysts have also recently issued reports about the company. Chardan Capital assumed coverage on MoonLake Immunotherapeutics in a research note on Friday, November 6th. They issued a "buy" rating and a $57.00 price objective on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of MoonLake Immunotherapeutics in a research note on Wednesday, September 16th. Wall Street Zen lowered shares of MoonLake Immunotherapeutics from a "sell" rating to a "strong sell" rating in a research report on Sunday, September 27th. Finally, Weiss Ratings upgraded shares of MoonLake Immunotherapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, August 21st. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $31.09.

MoonLake Immunotherapeutics Stock Down 0.5%

MLTX stock opened at $12.56 on Wednesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 9.13 and a current ratio of 9.13. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -3.42 and a beta of 1.14. MoonLake Immunotherapeutics has a fifty-two week low of $9.46 and a fifty-two week high of $23.29. The stock has a fifty day moving average of $12.01 and a 200-day moving average of $16.29.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.10).

Institutional Trading of MoonLake Immunotherapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Weiss Asset Management LP grew its holdings in MoonLake Immunotherapeutics by 413.1% during the 1st quarter. Weiss Asset Management LP now owns 1,708,328 shares of the company's stock valued at $31,843,000 after buying an additional 1,375,367 shares in the last quarter. Janus Henderson Group PLC increased its holdings in MoonLake Immunotherapeutics by 64.7% during the 1st quarter. Janus Henderson Group PLC now owns 3,451,628 shares of the company's stock worth $64,304,000 after acquiring an additional 1,355,640 shares during the period. Bank of America Corp DE lifted its stake in MoonLake Immunotherapeutics by 5,255.8% in the 1st quarter. Bank of America Corp DE now owns 724,794 shares of the company's stock worth $13,510,000 after purchasing an additional 711,261 shares in the last quarter. Exome Asset Management LLC purchased a new stake in MoonLake Immunotherapeutics in the 1st quarter worth approximately $4,015,000. Finally, Readystate Asset Management LP purchased a new stake in MoonLake Immunotherapeutics in the 1st quarter worth approximately $2,689,000. Hedge funds and other institutional investors own 93.85% of the company's stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a Switzerland-based clinical-stage biopharmaceutical company focused on developing treatments for inflammatory skin and joint diseases. The company was established in 2021 and is headquartered in Zug. Its lead investigational medicine, sonelokimab, is a nanobody designed to inhibit the inflammatory proteins IL-17A and IL-17F. MoonLake is studying the drug as a potential treatment for conditions including hidradenitis suppurativa, psoriatic arthritis and axial spondyloarthritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.